Drug: bevacizumab Quarter: 2016Q3
Total Records: 786 Number of Pages: 40
| DRUGNAME | PT | EventCount |
|---|---|---|
| Bevacizumab | Haemoglobin decreased | 18 |
| Bevacizumab | Deep vein thrombosis | 17 |
| Bevacizumab | Oedema peripheral | 17 |
| Bevacizumab | Gait disturbance | 16 |
| Bevacizumab | Hepatic failure | 16 |
| Bevacizumab | Hypoglycaemia | 16 |
| BEVACIZUMAB | Mouth ulceration | 16 |
| Bevacizumab | Hypermagnesaemia | 15 |
| Bevacizumab | Hypoacusis | 15 |
| BEVACIZUMAB | Ill-defined disorder | 15 |
| Bevacizumab | Infection | 15 |
| Bevacizumab | Pneumonitis | 15 |
| Bevacizumab | Cerebrovascular accident | 14 |
| BEVACIZUMAB | Emotional disorder | 14 |
| Bevacizumab | Gastrointestinal perforation | 14 |
| Bevacizumab | Lower gastrointestinal haemorrhage | 14 |
| Bevacizumab | Malaise | 14 |
| Bevacizumab | Rectal haemorrhage | 14 |
| Bevacizumab | Urinary retention | 14 |
| Bevacizumab | Electrolyte imbalance | 13 |
Total Records: 786 Number of Pages: 40